4//SEC Filing
BIOTECHNOLOGY VALUE FUND L P 4
Accession 0000921895-25-001784
CIK 0001253689other
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 6:53 PM ET
Size
35.5 KB
Accession
0000921895-25-001784
Insider Transaction Report
Form 4
BIOTECHNOLOGY VALUE FUND L P
10% Owner
Transactions
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Common Stock
2025-06-13+657,308→ 707,116 total
Transactions
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying)
BVF II GP LLC
Other
Transactions
- Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying)
BVF INC/IL
10% Owner
Transactions
- Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying)
BVF PARTNERS L P/IL
10% Owner
Transactions
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total
BVF Partners OS Ltd.
Other
Transactions
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Common Stock
2025-06-13+657,308→ 707,116 total
BVF GP HOLDINGS LLC
10% Owner
Transactions
- Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total
BVF I GP LLC
10% Owner
Transactions
- Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total
Transactions
- Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying)
LAMPERT MARK N
10% Owner
Transactions
- Other
Common Stock
2025-06-13+556,617→ 593,740 total - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+257,515→ 257,515 total→ Common Stock (257,515 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+304,098→ 304,098 total→ Common Stock (304,098 underlying) - Other
Pre-Funded Warrants to Purchase Common Stock
2025-06-13+25,944→ 25,944 total→ Common Stock (25,944 underlying) - Other
Common Stock
2025-06-13+657,308→ 707,116 total - Other
Common Stock
2025-06-13+56,079→ 62,383 total
Footnotes (7)
- [F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- [F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- [F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- [F5]On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.
- [F6]Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.
- [F7]Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.
Documents
Issuer
GLYCOMIMETICS INC
CIK 0001253689
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0000918923
Filing Metadata
- Form type
- 4
- Filed
- Jun 16, 8:00 PM ET
- Accepted
- Jun 17, 6:53 PM ET
- Size
- 35.5 KB